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Abstract
Enfuvirtide and T-1249 are two HIV-1 fusion inhibitor peptides that bind to gp41 and prevent its fusogenic conformation,
inhibiting viral entry into host cells. Previous studies established the relative preferences of these peptides for membrane
model systems of defined lipid compositions. We aimed to understand the interaction of these peptides with the
membranes of erythrocytes and peripheral blood mononuclear cells. The peptide behavior toward cell membranes was
followed by di-8-ANEPPS fluorescence, a lipophilic probe sensitive to the changes in membrane dipole potential. We
observed a fusion inhibitor concentration-dependent decrease on the membrane dipole potential. Quantitative analysis
showed that T-1249 has an approximately eight-fold higher affinity towards cells, when compared with enfuvirtide. We also
compared the binding towards di-8-ANEPPS labeled lipid vesicles that model cell membranes and obtained concordant
results. We demonstrated the distinct enfuvirtide and T-1249 membranotropism for circulating blood cells, which can be
translated to a feasible in vivo scenario. The enhanced interaction of T-1249 with cell membranes correlates with its higher
efficacy, as it can increase and accelerate the drug binding to gp41 in its pre-fusion state.
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Introduction
The Human Immunodeficiency Virus type 1 (HIV-1) is a highly
pathogenic, evasive and difficult to eradicate agent that causes
Acquired Immunodeficiency Syndrome (AIDS). This discovery in
the early 1980s triggered major international scientific efforts in
antiviral drug discovery and development [1]. As a consequence,
many drugs are now available to manage this condition, allowing
the use of drug combination therapy known as HAART (highly
active antiretroviral therapy). The majority of the drugs inhibit the
different enzymes vital for the HIV-1 life cycle: reverse
transcriptase, integrase and protease. However, the entry inhib-
itors target steps before the viral content is released into the host
cell cytoplasm [2]. Infection of T CD4
+ cells begins with the
binding of the viral envelope trimeric glycoprotein gp120 with the
CD4 receptor and a chemokine receptor (CCR5 or CXCR4) of
the host cell. This engagement triggers the exposure of the
hydrophobic N-terminal region of another envelope glycoprotein,
gp41. This fusion peptide anchors to the membrane of the host
cell, enabling the two gp41 helical heptad repeat domains, the C-
terminal (CHR or HR2) and the N-terminal (NHR or HR1), to
fold into each other to form a hairpin-like structure (6-helix
bundle). This approximates the cell and the viral membranes,
facilitating their fusion and the release of the viral content into the
cell [3].
Besides maraviroc, a recently approved CCR5 antagonist
blocking gp120 co-receptor engagement [4], enfuvirtide is the
other only entry inhibitor approved for clinical use [5]. Enfuvirtide
(formerly known as T-20 and DP-178) is a peptide drug selected
from chemically synthesized peptides derived from various regions
of gp41 [6]. The core structure of gp41 was only revealed later and
helped to understand the inhibitory activity of enfuvirtide [7]. The
peptide sequence (sequence 643–678 of HIV-1LAI [6]) corre-
sponded partially to the CHR region of gp41 and it would bind to
the opposite NHR region, preventing the formation of the hairpin
structure and consequently, the fusion. The same consortium that
led enfuvirtide to clinical approval (Trimeris, Inc. and Roche)
developed a second generation fusion inhibitor, T-1249. It is a 39-
mer peptide which sequenced was designed taking into account
the gp41 CHR sequences from HIV-1, HIV-2 and SIV (Simian
Immunodeficiency Virus) [8]. A successful short-term evaluation
of antiretroviral activity and safety in humans proved the potential
of this new drug [8], although further clinical development was put
on hold [9].
Since the first appearance of enfuvirtide, the search for peptide
drugs against HIV has been a growing field of research and several
candidates proved to be efficient in vitro [10]. As our knowledge of
HIV structure and function progresses, more sophisticated peptide
designs are developed in order to overcome viral resistance to
previous drugs. The initial view of the mechanism of action of
these peptides, that is, binding to NHR region and block 6-helix
bundle formation, has been refined over the years. Other factors
besides gp41-peptide binding can contribute to explain the mode
of action of these peptides. In fact enfuvirtide does not form stable
6-helix bundle structures with N36, a NHR derived peptide,
contrary to C34, another CHR derived peptide [11]. Moreover,
peptides derived from the membrane-spanning domain in gp41
and the co-receptor binding site in gp120 inhibited enfuvirtide
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envelope could be targeted by enfuvirtide.
Membrane binding/tropism emerged as an important factor to
take into account concerning the mode of actions of these peptides.
Previous studies evaluated the preferences of enfuvirtide and T-
1249 to membrane model systems. Partition of these peptides to
fluid phase and cholesterol-rich lipid vesicles was followed by
intrinsic tryptophan fluorescence present in both peptides [12,13].
Both enfuvirtide [13] and T-1249 [12] partitioned to fluid phase
zwitterionic phospholipid vesicles (POPC, 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine) with partition constants (Kp [14]) of
1.6610
3 and 5.1610
3, respectively. However, regarding interac-
tion with cholesterol-rich POPC vesicles (up to 33% mol)
enfuvirtide showed residual association, while T-1249 binding
was significant, despite also presenting a low partition (membrane
insertion) [12]. T-1249 improved preference for lipid environment
correlated with its higher antiviral activity.
In this study, we aim to understand the nature of HIV-1 fusion
inhibitors-membrane interactions using human blood cells,
namely erythrocytes and PBMC (peripheral blood mononuclear
cells). We made use of an indirect reporter, the fluorescent
lipophilic probe di-8-ANEPPS, as direct measure of the peptide
intrinsic tryptophan fluorescence was impracticable with cells.
This probe incorporates in the outer leaflet of the cell membranes
and is sensitive to the local dipole potential by shifting its excitation
spectrum [15]. Interaction of peptides or other molecules with
membranes can change the lipid and interfacial water dipoles
organization. Moreover, the peptide dipoles themselves can
contribute to the potential. These overall dipolar changes
occurring at the membrane can then be translated by the probe
both qualitatively and quantitatively [16].
Results
Labeling of erythrocytes and PBMC with di-8-ANEPPS
membrane probe
Isolated human erythrocytes and PBMC membranes were
successfully labeled with di-8-ANEPPS. Confocal microscopy
images clearly show the delineated labeled membrane
(Fig. 1A,B). Importantly, no intracellular staining of di-8-ANEPPS
was observed. The emission and excitation spectra of the probe
were taken for the two cell types (Fig. 1C). Labeled erythrocytes
and PBMC had different spectral maxima (specially for the
emission) due to the probe sensitivity to the differences in the
composition and nature of the membrane lipids.
Enfuvirtide and T-1249 induce changes in the dipole
potential of cell membranes
Incubation of the labeled erythrocytes and PBMC with
enfuvirtide or T-1249, lead to changes in spectral properties of
the membrane-bound di-8-ANEPPS. Excitation spectra were
deviated to the red meaning that a decrease in the dipole potential
occurs. Differential spectra can be used in order to help the
visualization of the spectral shift (Fig. 2). In this case, the minimum
of the differential spectra comes at a lower wavelength than the
maximum, indicative of a decrease in the dipole potential (see
methods section). These changes depend on the peptide and its
concentration. T-1249 is more effective in decreasing the
membrane potential than enfuvirtide.
To follow the time course of the interaction, we used the ratio
between the approximate maximum and minimum of the
differential spectra (R = I455 nm/I525 nm), that correlates with
the dipole potential variations. After the addition of each peptide,
we observed a decrease on the dipole potential within the first
minutes for erythrocytes (Fig. 3) and lymphocytes.
Quantification of the membrane-peptide interaction for
erythrocytes and PBMC
In order to quantify the affinity of the peptides to the cell
membranes, we set to investigate the variation of the dipole
potential as a function of peptide concentration (Fig. 4). The ratio
R was measured for a range of concentrations of enfuvirtide and
T-1249. The decrease of the potential as a function of
concentration followed a hyperbolic curve. The data was analyzed
according to a single binding site model [17] to yield dissociation
constants (Kd) for each peptide (Table 1). For both cell types, the Kd
for T-1249 was much smaller (one order of magnitude),
accounting for a higher preference for the cell membrane. The
Figure 1. Visualization and spectral characterization of di-8-
ANEPPS labeled cells. Labeled erythrocytes (A) and PBMC (B) were
observed under a confocal fluorescence microscope to confirm that
only the plasma membrane was stained (shown in red). Additional
staining of the nucleus with Hoechst dye (blue) was performed for
PBMC, only for microscopy observation. Excitation and emission spectra
(C) were taken for each labeled cell type, differing on peaks due to
different membrane environments (blue trace for PBMC and red trace
for erythrocytes; filled line for excitation and dashed line for emission
spectra). Excitation at 465 nm for both cell types; emission at 600 nm
and 585 nm for erythrocytes and PBMC, respectively.
doi:10.1371/journal.pone.0009830.g001
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PBMC membrane seems to be maintained: the ratios Kd,ENF/Kd,T-
1249 are similar for both cell type (8.5 and 8.1 for erythrocytes and
PBMC, respectively).
Comparison of peptide-induced dipole changes in bio-
mimetic lipid vesicles
As stated earlier, interaction of enfuvirtide and T-1249 with
lipid vesicles has been previously studied by means of their
tryptophan residues fluorescence. For the sake of comparison with
the data obtained for the interaction with blood cells membranes
and in order to validate the comparison with previous data, we
used di-8-ANEPPS labeled lipid vesicles to assess the interaction of
these peptides, reported by changes on membrane dipole potential
(Fig. 5). The lipid vesicles were composed entirely of POPC, to
mimic most of the outer leaflets of mammalian cell membranes, in
the liquid disordered state, or a mixture of POPC with cholesterol
33% mol, as an approximation to the membrane microdomains in
the liquid ordered state (lipid rafts). This is especially relevant for
the erythrocyte membranes, which are particularly cholesterol-rich
[18]. Concerning the POPC vesicles, the binding of T-1249 was
again more pronounced than for enfuvirtide (Fig. 5). When the
vesicles are enriched with cholesterol, significant changes occur in
terms of peptide association to the membrane. Enfuvirtide binds
less extensively to membranes rich in cholesterol, while T-1249
increases the extension of membrane association (Fig. 5). This is in
agreement with previous results obtained for lipid vesicles [12], in
which the adsorption of T-1249 on cholesterol enriched domains
was identified, in contrast to enfuvirtide.
Discussion
Designing peptide drugs based in gp41 sequence to prevent viral
entry into host cells has been in focus in the antiretroviral research
field. Several factors related to their mode of action must be taken
into account in order to optimize efficacy. For the first time, we
addressed the interactions of HIV-1 fusion inhibitors with human
cell membranes to better understand their membranotropic
behavior in vivo. We made use of a dipole potential membrane
probe, di-8-ANEPPS, to indirectly assess the membrane binding of
enfuvirtide and T-1249 to erythrocytes and mononuclear
leukocytes. These peptides decreased the membrane dipole
potential of the two cell types, indicating that an interaction is
occurring. Quantitatively, T-1249 was found to have approxi-
mately 8 times more affinity towards these cell membranes than
enfuvirtide. Furthermore, studies with di-8-ANEPPS labeled
POPC vesicles corroborated this by showing higher binding of
T-1249 in comparison with enfuvirtide. Concerning POPC/
cholesterol vesicles, the relative binding affinity between the two
peptides was maintained. The presence of cholesterol reduced the
binding extension of enfuvirtide and had an opposite effect in the
case of T-1249, in agreement with our previous results that
followed the interaction by tryptophan fluorescence [12]. Due to
the fact that erythrocyte membranes contain significantly more
cholesterol than PBMC [18] it could be expected that peptide
binding characteristics for these two cell types would be more
distinct. However, these composition differences seem not to be
sufficient to change significantly the interaction behavior of the
Figure 2. Differential spectra of membrane-bound di-8-AN-
EPPS in the presence of HIV-1 fusion inhibitor peptides. The
shape of the difference spectra reveal spectral shift to the red, indicative
of a decrease in membrane dipole potential. For erythrocytes (top row)
and PBMC (bottom row), the higher the peptide concentration (150 mM
in blue, 40 mM in red and 10 mM in green), the higher the spectral shifts.
doi:10.1371/journal.pone.0009830.g002
Figure 3. Time course variation of dipole potential in response to the peptides. The effect of the addition of indicated concentrations (mM)
of enfuvirtide (A, red) and T-1249 (B, blue) to labeled erythrocytes was followed by measuring the ratio in real-time. Stepwise additions decreases the
ratio within minutes.
doi:10.1371/journal.pone.0009830.g003
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(33% mol) vesicles. Other factors such as the diversity of lipidic,
proteic and glycidic components seem to superimpose to the effect
of differences in cholesterol content. In fact, we checked if
cholesterol depletion of erythrocytes membranes by methyl-b-
cyclodextrin would reflect on changes in peptide binding and no
significant alterations were detected (data not shown).
The membranotropism of these peptides can be explained in
molecular terms by their structure and aminoacid sequence. It has
been identified in the CHR and adjacent regions specific motifs
that account for different roles in the interaction with NHR and
membrane environment. Some of these regions also translate to
the CHR derived peptides. Towards the N-terminus of CHR,
there is a pocket binding domain (PBD, HIV-1LAI 628–635) that
binds to a hydrophobic groove in the NHR region [7]. It was
established that this PBD was a crucial region for the binding of
CHR and NHR in order to form the 6-helix bundle hairpin-like
structure [7]. Another region identified in the far C-terminus of
CHR is the lipid binding domain (LBD), a hydrophobic Trp-rich
region by which CHR derived peptides can apparently bind to
lipid membranes [19]. The sequence of enfuvirtide contains only
the LBD while T-1249 was designed to contain both LBD and
PBD (Fig. 6A). Thus, binding to cell and mimetic membranes is
related to this putative LBD. Interestingly, by mutating the LBD
region of enfuvirtide WNWF to ANAA, the antiviral activity of the
peptide was abrogated [20] as well as its ability to bind to POPC
vesicles [19]. Moreover, when an ANAA enfuvirtide mutant was
octylated, its inhibitory activity was restored to a level similar to
standard enfuvirtide [21]. This indicates the importance of the
LBD for the efficacy of enfuvirtide, as the octylation of enfuvirtide
also increased its potency. A similar result was obtained when
enfuvirtide and ANAA mutant were expressed attached to a
membrane protein in a T-helper cell line [22]. Another example
comes from the addition of a cholesteryl group to C34, another
peptide fusion inhibitor that lacks a LBP but contains the PBD
sequence [23]. The potency of the derivatized C34 increased
significantly; however, this effect was not observed when
cholesterol was attached to enfuvirtide, which already has a
LBD. TRI-999, another LBD lacking C-peptide, was synthesized
with an attached C18 chain [24], showing improved efficiency
over enfuvirtide.
All these findings that relate membrane binding to improved
efficiency of the peptides mean that this is a major factor to take
into account when rationally designing drugs of this type.
Enfuvirtide and T-1249 have membranotropic behavior towards
POPC lipid vesicles and now this study confirms that they both
Figure 4. Peptide affinity towards erythrocytes and PBMC cell membranes. The dependence of the ratio on the enfuvirtide (red) and T-1249
(blue) concentrations for erythrocytes (A) and PBMC (B) was analyzed by a single binding site model (dashed lines) in order to quantify the
dissociation constants (see Table 1). Ratio values were normalized for the initial value of zero peptide concentration. Plotted values represent the
mean 6 SEM (error bars not visible in erythrocytes due to small errors). N=6 for erythrocytes and N=7 for PBMC.
doi:10.1371/journal.pone.0009830.g004
Table 1. Quantification of peptide binding.
Cells Peptide Rmin, norm Kd (mM) Kd, ENF/Kd, T-1249
Erythrocytes T-1249 20.8160.0063 4.1660.13 8.5
Enfuvirtide 20.9760.015 35.461.33
PBMC T-1249 20.7760.014 7.7160.61 8.1
Enfuvirtide 21.060.071 62.2610.2
Comparison of the values of the dissociation constant, Kd and the parameter
Rmin obtained by non-linear regression with equation (1). The values represent
mean 6 SEM.
doi:10.1371/journal.pone.0009830.t001
Figure 5. Interaction of the peptides with membrane model
systems. The binding profiles for enfuvirtide (red) and T-1249 (blue)
were obtained for large unilamellar vesicles composed of POPC (open
symbols) and POPC/cholesterol 33% mol (filled symbols).
doi:10.1371/journal.pone.0009830.g005
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restricted temporal and spatial window of opportunity to bind to
their molecular target: the NHR region of gp41 in its extended
conformation when the virus and host cell are closely engaged.
This makes aqueous diffusion of the peptide to the target less
efficient. The capacity that these peptides have to bind to the cell
membranes facilitates the delivery of the peptides to this confined
environment, as some peptide is already locally present.
Ultimately, the membrane can act as a ‘‘catalyst’’ to the binding
reaction between the gp41 and the peptides, as it has been
postulated in other receptor-ligand scenarios in the membrane
environment [25]. Thus, for this case, the higher potency of T-
1249 in relation to enfuvirtide seems to correlate with its higher
membranes binding to the blood cells, particularly the lympho-
cytic fraction, where the preferential target cells are included.
Then, its membrane binding capacity is possibly one of the
factors that explain their relative potency (Fig. 6B). In terms of its
structure and sequence, both peptides have the LBD sequence
that accounts almost totally for enfuvirtide membrane binding.
Nevertheless, T-1249 should have some other structural charac-
Figure 6. Proposed mode of action of enfuvirtide and T-1249 in circulation with blood cells. A) Sequence alignment of enfuvirtide and T-
1249 with native gp41 (PDB code: 1ENV), showing the pocket binding domain (PBD) in blue and the putative lipid binding domain (LBD) close to the
membrane proximal region in red. B) Peptides partition to the membranes of circulating blood cells creating a peptide-rich environment, when the
virus interact both with erythrocytes and lymphocytes. HIV associates with erythrocytes via DARC receptor or complement opsonized virus via CR1.
Exchanges of peptide between cells and virus and partition of peptide directly to the viral membrane can occur. When infecting the preferential CD4
+
T cells, the membrane binding of peptide inhibitors should facilitate its interaction with the exposed conformation of gp41, preventing the 6-helix
bundle formation. If the virus is internalized and fuses with the cell membrane at the endosome level, as recently described [27], the partition of the
peptides to the membranes ensures that a considerable amount of peptides enters upon endocytosis in order to be available during the intracellular
fusion event.
doi:10.1371/journal.pone.0009830.g006
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region additionally present on T-1249 is also a hydrophobic
region and has 2 tryptophan residues (LBD has 3 Trp). This
could account for a weak membrane binding domain. However,
the membrane binding capacity of a C-peptide with an altered
heptad repeat sequence and containing a PBD but not a LBD
(PBD-4HR, similar do C34) is very poor, similar to a C-peptide
that does not have any of these domains [26]. We could speculate
that a possible, but not certain, synergistic action between the
PBD and LBD domains present on T-1249 to increase its
membranotropism. Another contributing factor could be the
increased helicity of T-1249 in solution compared to enfuvirtide
[12], a structural characteristic that favors insertion and stability
in the membrane. Summarizing, T-1249 would be more effective
due to: a) a LBD sequence motif, shared with enfuvirtide, that
allows the peptide to anchor to the membrane as a platform to
reach the target sequence in gp41 and explains part of its
membranotropism; b) a PBD sequence motif that accounts for an
enhanced gp41 binding and c) the higher overall affinity towards
cell membranes of T-1249 (especially cholesterol-rich domains)
not explained by the sum of the membrane binding effects of
PBD and LBD.
Recently, a novel discovery about the HIV-1 entry into host
cells challenged the current knowledge of viral-cell membrane
fusion at the cell surface. Miyauchi et al. [27] showed that HIV-1
tends to prefer an endocytic route of entry and that fusion
preferentially occurs at the endosomes. This would elicit
protection to HIV from fusion inhibitors, as the surface exposition
of the gp41 extended conformation is reduced. Hence, the
capability of peptide fusion inhibitors to partition to the membrane
and remain there while the virus is internalized, together with a
cell membrane patch, can prove to be a decisive factor concerning
their inclusion on the endosome, leading to increased antiretro-
viral efficacy and potency.
The relevance of peptide binding to erythrocytes is not to be
diminished. In fact, HIV can be found associated with erythrocytes
in vivo [28] and binds to erythrocyte membrane in vitro [29]. The
virus can bind to erythrocytes via the DARC (Duffy Antigen
Receptor for Chemokines) [30,31] or via the complement receptor
1 (CR-1), that binds C3b or C3bi opsonized virus [32,33].
Moreover, erythrocytes can mediate trans-infection of these bound
viruses to other immune system cells that circulate in the blood
and reside in the spleen [30,32]. Interestingly, depending on which
complement proteins are opsonizing the virus, they can direct the
virus through various immune system cells that express different
complement receptors, creating a dynamic circulation of the virus
and facilitating its spreading through the body [34]. Therefore, we
can speculate that by contacting with erythrocytes with pre-bound
fusion inhibitor peptides, the virus itself can take peptide in its own
membrane (Fig. 6B). In fact, Aloia et al. [35] found the lipid
composition of the erythrocyte membrane to be similar to the HIV
membrane itself; thus, peptide-viral membrane interaction seems
to be very feasible. This peptide-membrane interaction can occur
also for other circulating cells.
In a therapeutic context, several factors can influence the
availability of the antiretroviral peptides in circulation. The drug is
distributed to different components of the blood, namely, dissolved
in the plasma, bound to plasma proteins (namely, albumin) and, as
we established with this study, bound to cell membranes. The
membrane-bound fraction would enhance the availability towards
the molecular target in the virus, as explained earlier in this
section, opposing to the fraction bound to plasma proteins, a factor
that enhances peptide clearance. In conclusion, the dynamics
between the peptide interaction among the different cell
populations and with the virus, along with emerging new
perspectives of HIV entry are complex factors that should the
taken in consideration when rationally designing the next
generation of fusion inhibitor peptides.
Materials and Methods
Isolation and labeling of human erythrocytes and PBMC
Human blood samples were obtained from healthy volunteer
donors at the public blood bank Instituto Portugue ˆs do Sangue
(Lisbon, Portugal), with their informed written consent. These
samples were obtained under an institutional agreement between
IPS Lisboa and Instituto de Bioquı ´mica from Faculdade de
Medicina da Universidade de Lisboa. This study was approved by
the Ethics Committee of Faculdade de Medicina da Universidade
de Lisboa. Donors were asked to give up to 10 mL of blood for
research purposes additionally to their common blood donation of
450 mL to the blood bank. The blood collection was made
anonymously as the data treatment resulting from the experiences
made with these samples. The samples were drawn to K3EDTA
anticoagulant tubes (Vacuette, Greiner Bio-one, Kremsmu ¨nster,
Austria). For erythrocytes, the blood samples were centrifuged at
1200 g during 10 min to remove plasma and buffy-coat. The
erythrocytes were washed at least two times with working buffer
(HEPES 10 mM pH 7.4, in NaCl 150 mM, both from Sigma, St.
Louis, MO, USA). For labeling, they were prepared at 1%
hematocrit in working buffer supplemented with 0.05% (m/V)
Pluronic F-127 (Sigma) and di-8-ANEPPS 10 mM (Molecular
Probes, Invitrogen, Carlsbad, CA, USA). PBMC were isolated by
density gradient using Ficoll-Paque Plus (GE Healthcare, Little
Chalfont, UK), accordingly to manufacturer’s instructions. Cells
were counted in Cell-Dyn 1600 analyzer (Abbott, Abbott Park, IL,
USA) and were prepared at 3000 cells/mL in Pluronic supple-
mented buffer with di-8-ANEPPS 3.3 mM. The suspensions of
erythrocytes or PBMC with probe were incubated at room
temperature with gentle agitation for 1 h. Unbound di-8-ANEPPS
was removed by two wash cycles, with centrifugations at 1500 g for
5 min.
Preparation and labeling of lipid vesicles
Large unilamellar vesicles (LUV) with ,100 nm diameter,
composed of pure POPC (Avanti Polar Lipids, Alabaster, AL,
USA) or POPC with 33% mol cholesterol (Sigma), were obtained
by extrusion of multi-lamellar vesicles (MLV) as described
elsewhere [36]. Briefly, a chloroform dissolved lipid was dried in
round-bottom flasks to obtain a film. MLV were obtained by
dissolving the film in working buffer and subjecting to 8 freeze-
thaw cycles. The suspension was extruded, first through a
polycarbonate filter with 400 nm pores, followed by passages
trough 100 nm pores filters in a custom made extruder. For
cholesterol enriched vesicles, the extruder was heated by a water
bath. Lipid vesicles suspensions with 500 mM of total lipid were
incubated overnight with di-8-ANEPPS 10 mM, to ensure
maximum incorporation of the probe.
Fusion inhibitor peptides
The HIV-fusion inhibitors enfuvirtide (T-20) and T-1249 (kind
gifts of Roche, Palo Alto, CA, USA) were prepared in working
buffer at maximum stock concentration of 250 mM. These
peptides were incubated at different concentrations with labeled
erythrocytes (0.02% hematocrit), PBMC (100 cells/mL) or lipid
vesicles (200 mM of total lipid) during 1 h for cells or 90 min for
vesicles, with gentle agitation before measurements.
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Erythrocyte microscopy images were obtained in a laser
scanning confocal microscope Zeiss LSM 5 Live (Jena, Germany)
using a water immersion objective Zeiss C-Apochromat 206(1.20
numerical aperture). PBMC images were obtained in a Zeiss
LSM510 Meta using an oil immersion objective Zeiss Plan-
Apochromat 636 (1.4 numerical aperture). Di-8-ANEPPS was
excited by a 488 nm laser (LP 505 filter for erythrocytes, BP 575–
615 for PBMC). For the PBMC, Hoescht dye (Molecular Probes,
Invitrogen) was also used for nucleus labeling, excited by a 405 nm
laser (LP 420 filter).
Membrane dipole potential assessed by di-8-ANEPPS
The membrane probe di-8-ANEPPS assesses dipole potential by
shifting its excitation spectrum. Differential spectra for detecting
these shifts are obtained by subtracting the excitation spectrum of
labeled cells in the presence of peptide from the spectrum in its
absence. Before subtraction the spectra were normalized to the
integrated areas to reflect only spectral shifts. The differential
spectra are waveform shaped, which amplitude directly correlates
with the peak shifting magnitude, and hence, with the dipole
potential variation. Blue-shifts will result in differential spectra in
which a maximum comes at a lower wavelength than the
maximum, and the opposite for red-shifts.
To qualitatively define a value for the spectral shift and hence,
the dipole potential, a ratio was established from fluorescence
intensities at two wavelengths on the sides of excitation spectrum
peak [15,37]. We chose them by taking the corresponding
wavelength values for the minimum and the maximum of the
differential spectra, defining the ratio R for this case as I455 nm/
I525 nm (I, fluorescence intensity). It was already established that an
increase in the membrane dipole potential leads to a blue-shift in
the membrane incorporated di-8-ANEPPS and, consequently, to
an increase in the ratio [15,37]. We also made a simple test for
erythrocytes by adding 6-ketocholestanol (Sigma), an agent that
increases dipole potential, and we observed the expected behavior
of di-8-ANEPPS.
The variation of R with the peptide concentration was analyzed
by a single binding site model [17], following equation 1, with the
R values normalized for R0, the value at zero peptide
concentration. Rmin defines the asymptotic minimum value of R
and Kd is the dissociation constant.
R=R0~1z
Rmin=R0 Peptide ½ 
Kdz Peptide ½ 
ðEq:1Þ
Fluorescence spectroscopy measurements
All the fluorescence spectroscopy measurements were made in a
Varian Cary Eclipse (Mulgrave, Australia) fluorescence spectro-
photometer. Membrane-bound di-8-ANEPPS excitation spectra
and ratios were taken with emission at 670 nm in order to avoid
membrane fluidity effects, as previously tested for lipid vesicles
[38]. We also tested if this was observed in labeled erythrocytes
(data not shown). The R values were measured through
temperatures from 15uCt o5 0 uC, with emissions at 580, 600
and 670 nm. The slope was lower for 670 nm, meaning a lower
interference of fluidity effect at this wavelength. Excitation and
emission slits for all measurements were 5 nm and 10 nm,
respectively.
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